-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-506054-20-00
5
2024-06-05
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
-
2023-505928-59-00
5
2024-04-15
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2023-503575-21-00
5
2024-01-23
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)
-
2023-505054-17-00
6
2023-09-15
metastatic TTF-1 negative lung adenocarcinoma
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2023-509943-28-00
5
2022-05-18
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
-
2023-507469-24-00
4
2022-04-30
Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodyspl
-
2024-512148-50-00
5
2022-03-03
Non-small cell lung cancer
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2024-517761-17-00
4
2021-05-31
Multiple Myeloma
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-508214-42-00
5
2020-05-25
Previously treated locally advanced and unresectable or metastatic
non
-
2024-512682-14-00
4
2020-04-06
Non-resectable hepatocellular carcinoma (HCC)
-
2024-513947-94-00
4
2020-03-30
locally advanced (stage III) and not suitable for curative treatment,
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer